[Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Eosinophilia may be associated with reactive conditions and with clonal disorders of the hematopoietic cells. The hypereosinophilic syndrome takes an intermedier place in this group. In this disease a sustained eosinophilia with end organ damage can occur. The author summarized the diagnostic procedures and differential diagnosis in the group of these diseases focusing on characteristics and treatment of hypereosinophilic syndrome. The treatment has been varied and included steroids, hydroxyurea, interferon-alpha, and in some cases chemotherapy. On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the tyrosine kinase inhibitor imatinib mesylate (Glivec) would be effective.
Borbényi
Zita
Z
Szegedi Tudományegyetem, Szent-Györgyi Albert Orvos- és Gyógyszerésztudományi Centrum, II. Sz Belgyógyászati Klinika és Kardiológiai Központ, Szeged.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D003663:Decision Trees; D004802:Eosinophilia / Q000175:diagnosis / Q000188:drug therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000378:metabolism*; D039221:mRNA Cleavage and Polyadenylation Factors / Q000378:metabolism*
D001549:Benzamides; D005938:Glucocorticoids; D016898:Interferon-alpha; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D011505:Protein-Tyrosine Kinases; D020796:Receptor, Platelet-Derived Growth Factor alpha; D006918:Hydroxyurea